Evaluation of Liquid Biopsy NGS Assay Kits to Improve Access to Rapid, Decentralized Biomarker Testing for NSCLC in Daily Practice
Time: 4:00 pm
day: Day One Track B (1)
Details:
- Access to cost effective, easy to use, distributed NGS kits for liquid biopsy testing (LBx) are critical to helping support more rapid treatment decision making for cancer patients. These kit-based methods allow a broad range of laboratories to perform high-quality NGS testing, which improves patient access to targeted therapies in a short turnaround time
- Kitted LBx assays can typically be categorized into either amplicon-based targeted panels or hybrid capture based CGP assays, with varying costs, NGS workflows, including automation of different steps and resulting genomic content
- A summary of our evaluation on site of multiple NGS-based LBx products, review their features and benefits and discuss how they might be used clinically to help more effectively and rapidly genomically profile patients for a better care in advanced NSCLC
